Real-World Data on the Use of Follitropin Delta in a Dutch IVF Center

How does follitropin delta administered with an individualized dose based on body weight and AMH perform in daily practice, and is this comparable to results from a randomized phase III clinical trial in terms of ovarian response, pregnancy, and safety?

This is a descriptive analysis of real-world data obtained from the Erasmus University Medical Centre (EMC). Patients were treated with the dose of follitropin delta calculated according to the algorithm described in the ESTHER-1 trial. Outcome data were restricted to the first IVF cycle in patients with a regular ovulatory cycle treated with a GnRH antagonist protocol for whom the intended day of embryo transfer was day 5.

The ongoing pregnancy rate was 30.8% per started cycle, which is equivalent to the ESTHER-1 trial. The number of oocytes retrieved (10.3 ± 5.4) was also comparable. All other ovarian response parameters were within the range that was expected on the basis of the results of the ESTHER-1 trial.

The use of follitropin delta in a real-world clinical setting results in ovarian response outcomes comparable in range to those in the follitropin delta arm of the ESTHER-1 registration trial. No differences were observed in treatment outcomes.